{"name": "Conatus Pharmaceuticals",
 "permalink": "conatus-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/conatus-pharmaceuticals",
 "homepage_url": "http://www.conatuspharma.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@conatuspharma.com",
 "phone_number": "",
 "description": "",
 "created_at": "Sat Feb 12 11:47:09 UTC 2011",
 "updated_at": "Mon Jun 17 10:07:52 UTC 2013",
 "overview": "\u003Cp\u003EConatus Pharmaceuticals  is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       39],
      "assets/images/resized/0012/1771/121771v1-max-150x150.jpg"],
     [[197,
       52],
      "assets/images/resized/0012/1771/121771v1-max-250x250.jpg"],
     [[197,
       52],
      "assets/images/resized/0012/1771/121771v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$28.5M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://pharmalive.com/News/Index.cfm?articleid=761182",
    "source_description": "Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing",
    "raised_amount": 20000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 2,
    "funded_day": 11,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "AgeChem Venture Fund",
         "permalink": "agechem-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               27],
              "assets/images/resized/0006/8086/68086v1-max-150x150.jpg"],
             [[250,
               45],
              "assets/images/resized/0006/8086/68086v1-max-250x250.jpg"],
             [[343,
               63],
              "assets/images/resized/0006/8086/68086v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Aberdare Ventures",
         "permalink": "aberdare-ventures",
         "image":
          {"available_sizes":
            [[[150,
               28],
              "assets/images/resized/0005/3038/53038v1-max-150x150.jpg"],
             [[250,
               47],
              "assets/images/resized/0005/3038/53038v1-max-250x250.jpg"],
             [[300,
               57],
              "assets/images/resized/0005/3038/53038v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Advent Venture Partners",
         "permalink": "advent-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               60],
              "assets/images/resized/0001/6550/16550v3-max-150x150.png"],
             [[250,
               100],
              "assets/images/resized/0001/6550/16550v3-max-250x250.png"],
             [[450,
               181],
              "assets/images/resized/0001/6550/16550v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Bay City Capital",
         "permalink": "bay-city-capital",
         "image":
          {"available_sizes":
            [[[150,
               24],
              "assets/images/resized/0004/8963/48963v1-max-150x150.png"],
             [[219,
               36],
              "assets/images/resized/0004/8963/48963v1-max-250x250.png"],
             [[219,
               36],
              "assets/images/resized/0004/8963/48963v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Gilde Healthcare Partners",
         "permalink": "gilde-healthcare-partners",
         "image":
          {"available_sizes":
            [[[150,
               44],
              "assets/images/resized/0005/3138/53138v2-max-150x150.png"],
             [[201,
               59],
              "assets/images/resized/0005/3138/53138v2-max-250x250.png"],
             [[201,
               59],
              "assets/images/resized/0005/3138/53138v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Roche Venture Fund",
         "permalink": "roche-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0004/6088/46088v1-max-150x150.jpg"],
             [[156,
               22],
              "assets/images/resized/0004/6088/46088v1-max-250x250.jpg"],
             [[156,
               22],
              "assets/images/resized/0004/6088/46088v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://money.msn.com/business-news/article.aspx?feed=PR\u0026Date=20110412\u0026ID=13301509\u0026topic=TOPIC_FINANCING\u0026isub=1",
    "source_description": "Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing",
    "raised_amount": 7500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 4,
    "funded_day": 12,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "MPM Capital",
         "permalink": "mpm-capital",
         "image":
          {"available_sizes":
            [[[150,
               142],
              "assets/images/resized/0004/5561/45561v1-max-150x150.png"],
             [[180,
               171],
              "assets/images/resized/0004/5561/45561v1-max-250x250.png"],
             [[180,
               171],
              "assets/images/resized/0004/5561/45561v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "partial",
    "source_url": "http://www.sec.gov/Archives/edgar/data/1383701/000138370113000002/xslFormDX01/primary_doc.xml",
    "source_description": "SEC",
    "raised_amount": 1001551.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 6,
    "funded_day": 12,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "4365 Executive Drive, Suite 200",
    "address2": "",
    "zip_code": "92121",
    "city": "San Diego",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": 2013,
   "pub_month": 6,
   "pub_day": 14,
   "stock_symbol": "NASDAQ :CNAT"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        90],
       "assets/images/resized/0012/1772/121772v1-max-150x150.jpg"],
      [[250,
        150],
       "assets/images/resized/0012/1772/121772v1-max-250x250.jpg"],
      [[450,
        270],
       "assets/images/resized/0012/1772/121772v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}